The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study

Table 2

On-treatment platelet reactivity and prevalence of ADP receptor blocker nonresponders in T2D and ND patients.

On-treatment platelet reactivity	T2D patients	ND patients	Significance
LTA with ADP induction (%)
Sample 1	57.2 ± 26.4	50.3 ± 22.3	NS
Sample 2	45.9 ± 31.3	37.0 ± 20.8	NS
PRI of VASP phosphorylation (%)
Sample 1	59.4 ± 30.9	60.0 ± 25.2	NS
Sample 2	33.9 ± 25.3	38.6 ± 29.3	NS
ADP receptor blocker nonresponders (% of patients/number of patients)	T2D patients	ND patients	Significance
ADP receptor blocker nonresponders
Sample 1	52.4%/11 patients	56.5%/26 patients	NS
Sample 2	33.3%/7 patients	30.4%/14 patients	NS